Seaport Therapeutics 3Q 2026: Net loss $26.4M, diluted loss per share $0.49— 10-Q Summary

What happened

Seaport Therapeutics reported a third-quarter 2026 net loss of $26.4 million, wider than its $22.5 million loss a year earlier. Diluted loss per share was $0.49 versus $9.43, a comparison the article attributes to a substantially higher weighted-average share count. The company is advancing several drug studies.

Confirmed

Global impact / market context

The wider quarterly loss adds to the company’s stated expectation of continued operating losses while it advances its drug pipeline. Spending on studies may continue to use cash before trial results arrive, making progress and future funding needs relevant to investors.

Analyst inference

The article gives no share-price reaction or cash balance, so it does not establish how investors have priced the results or how long available cash may last. The pipeline offers potential future trial data, but those results remain pending.

Analyst inference

What to watch

1. Watch for topline results from the Phase 2b BUOY-1 study of GlyphAllo, expected in the first half of 2027; these are headline findings from the trial. Confirmed
2. The company plans a Phase 2/3 generalized anxiety disorder trial in the first half of 2027; whether it starts as planned could shape development spending. Proposed
3. Track future loss and cash disclosures: continued losses alongside pipeline advancement could increase funding pressure if spending outpaces cash available. Analyst inference

Evidence

• Original source link unavailable